10.71
0.35 (3.38%)
| Previous Close | 10.36 |
| Open | 10.29 |
| Volume | 175,796 |
| Avg. Volume (3M) | 185,157 |
| Market Cap | 312,544,704 |
| Price / Sales | 11.15 |
| Price / Book | 2.51 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Diluted EPS (TTM) | -2.49 |
| Total Debt/Equity (MRQ) | 3.25% |
| Current Ratio (MRQ) | 21.47 |
| Operating Cash Flow (TTM) | -39.28 M |
| Levered Free Cash Flow (TTM) | -26.34 M |
| Return on Assets (TTM) | -22.95% |
| Return on Equity (TTM) | -33.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Contineum Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.82% |
| % Held by Institutions | 79.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sectoral Asset Management Inc | 30 Sep 2025 | 800,787 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (RBC Capital, 105.42%) | Buy |
| Median | 18.00 (68.07%) | |
| Low | 14.00 (Baird, 30.72%) | Buy |
| Average | 18.00 (68.07%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 10.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 24 Nov 2025 | 14.00 (30.72%) | Buy | 10.36 |
| RBC Capital | 21 Nov 2025 | 22.00 (105.42%) | Buy | 10.95 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Dec 2025 | Announcement | Contineum Therapeutics Announces Proposed $75.0 Million Public Offering |
| 11 Dec 2025 | Announcement | Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering |
| 24 Nov 2025 | Announcement | Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference |
| 20 Nov 2025 | Announcement | Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) |
| 30 Oct 2025 | Announcement | Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |